FY2025 · ended Dec 31, 2025 · Revenue $59,000, -86.6% YoY · Filed Mar 23, 2026
Avalo Therapeutics, Inc. (AVTX) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $59,000 and a net loss of $78.3 million. As of Sep 30, 2026 it held $462.8 million in cash and investments and $153,000 in total debt.
Revenue
$59,000
-86.6% vs prior year
Net income
$-78.26M
-122.8% vs prior year
Operating cash flow (TTM)
$-63.47M
-21.5% vs year-ago TTM
Free cash flow
$-26.85M
+62.2% vs prior year
EPS
$-5.84
+72.1% vs prior year
Dividend per share
None
Shares outstanding
22.79M
+113.5% vs prior year
Net cash
$462.62M
as of Sep 30, 2026
Operating margin
-123601.7%
FY 2025
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- AVTX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Wayne, PA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1534120
- Former names
- Cerecor Inc. (until Aug 18, 2021)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $59,000 | $441,000 | $1.9M | $18.1M | $5.4M |
| Operating income | -$72.9M | -$68.5M | -$27.4M | -$37.4M | -$82.1M |
| Net income | -$78.3M | -$35.1M | -$31.5M | -$41.7M | -$84.4M |
| Diluted EPS | -$5.84 | -$20.91 | -$113.58 | -$1,063.00 | — |
| Operating cash flow | -$51.5M | -$49.1M | -$30.7M | -$26.8M | -$70.9M |
| Free cash flow | — | — | — | -$26.8M | -$71.0M |
| Total assets | $116.5M | $150.7M | $21.0M | $33.4M | $80.2M |
| Total liabilities | $33.4M | $17.7M | $13.7M | $44.3M | $57.1M |
| Stockholders' equity | $83.0M | $133.0M | $7.3M | -$10.9M | $23.1M |
| Cash and investments | $98.3M | $134.5M | $7.4M | $13.2M | $54.6M |
| Total debt | $427,000 | $918,000 | $1.9M | $2.2M | $2.5M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Agreement ended
|
Nov 5, 2026 | Nov 5, 2026 |
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 5, 2026 | Nov 5, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Officer or director change
|
Jun 23, 2026 | Jun 23, 2026 |
All 1006 Avalo Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.